Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pacira BioSciences's Revenue for the
three
months ended in Mar. 2026 was €153.4 Mil. Pacira BioSciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was €107.3 Mil.
Hence, Pacira BioSciences's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.43.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pacira BioSciences Receivables Turnover Related Terms
Pacira BioSciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a Receivables Turnover of 1.43 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pacira BioSciences and its competitors. According to the industry distribution chart, Pacira BioSciences ranks #319 out of 950 companies in the Drug Manufacturers industry, placing it in the top 33.6%.
Is Pacira BioSciences' Receivables Turnover too high?
Pacira BioSciences' current Receivables Turnover is 1.43. The Drug Manufacturers industry median Receivables Turnover is 5.07. Pacira BioSciences' value of 1.43 is 71.8% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #319 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Receivables Turnover compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #319 out of 950 companies for Receivables Turnover. This puts Pacira BioSciences in the upper half of its industry. The industry median Receivables Turnover is 5.07. Pacira BioSciences' value of 1.43 is 71.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Receivables Turnover of 1.43 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Receivables Turnover is 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Receivables Turnover of 1.43. The stock's GF Value™ is €25.57, compared to a current price of €22.40 — trading 12.4% below its estimated fair value. The current Receivables Turnover is 1.43 and 71.8% below the Drug Manufacturers industry median of 5.07. Pacira BioSciences' overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Receivables Turnover is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 12.4% below its estimated GF Value™ of €25.57.
Key valuation signals for FRA:82P:
Receivables Turnover: 1.43
GF Value™: €25.57 vs. price of €22.40 (12.4% below fair value)
Industry Position: 71.8% below the Drug Manufacturers median (#319 of 950)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
83GF Score
Get the complete analysis for FRA:82P
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
